Navigation Links
Unilife Corporation Reschedules Release Of Quarterly Results And Earnings Call Due To Severe Weather In Northeastern U.S.
Date:10/29/2012

YORK, Pa., Oct. 29, 2012 /PRNewswire/ -- Unilife Corporation ("Unilife" or "Company") (NASDAQ: UNIS;  ASX: UNS) announced today that, due to severe weather conditions and expected power outages in the Northeastern region of the U.S., it has decided to reschedule the release of its results for the fiscal 2013 first quarter ended September 30, 2012.  Unilife will now release its fiscal 2013 first quarter results and 10-Q on Thursday, November 8 at 4:05 p.m. (U.S. Eastern Standard Time).

The Unilife conference call with analysts will be rescheduled to occur on Thursday, November 8 at 4:30 p.m. (U.S. Eastern Standard Time) (Australian time is Friday, November 9, 2012 at 8:30 a.m. AEDT).  The conference call will be broadcast over the Internet as a "live" listen only Webcast. To listen, please go to: http://ir.unilife.com/events.cfm. Listeners are urged to login approximately 20 minutes before the conference call is scheduled to begin in order to register, as well as download and install any necessary audio software. An archive of the webcast will be available on the Company's website.

Shareholders seeking an update on Unilife prior to November 8th are encouraged to refer to a two-part video interview series conducted with an analyst from Griffin Securities, Inc. that was released by the Company last week. The video interviews and associated transcripts are available on the Unilife website at www.unilife.com. The videos are also available on YouTube: video 1: http://youtu.be/X-LbVnzk1W0; and video 2: http://youtu.be/tDTeWn6UJLQ.About Unilife CorporationUnilife Corporation (NASDAQ: UNIS / ASX: UNS) is a U.S. based developer and commercial supplier of advanced drug delivery systems. Unilife collaborates with pharmaceutical and biotechnology companies seeking innovative, differentiated devices that can enable or enhance the delivery of injectable drugs and vaccines supplied in either a liquid stable or lyophilized form. The Unifill syringe, the world's first and only prefilled syringe with fully integrated safety features, sits at the leading edge of this diversified portfolio. In addition to prefilled and hypodermic safety syringes with automatic, user-controlled needle retraction, Unilife has other proprietary technology platforms including drug reconstitution delivery systems, auto-injectors, auto-infusion pump systems and specialized devices for targeted organ delivery. Unilife's global headquarters and state-of-the-art manufacturing facilities are located in York, PA. For more information on Unilife, please visit www.unilife.com.Forward-Looking Statements This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in "Item 1A. Risk Factors" and elsewhere in our Annual Report on Form 10-K and those described from time to time in other reports which we file with the Securities and Exchange Commission. 

General: UNIS-G Investor Contacts (US): Analyst EnquiriesInvestor Contacts (Australia)Todd Fromer / Garth RussellLynn PieperJeff CarterKCSA Strategic CommunicationsWestwicke PartnersUnilife CorporationP: + 1 212-896-1215 / 212-896-1250

P: + 1 415-202-5678

P: + 61 2 8346 6500 


'/>"/>
SOURCE Unilife Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Second Part of the Griffin Securities Analyst Interview with Unilife Corp. CEO is Now Available
2. Unilife Corporation To Announce Financial Results For Fiscal 2013 First Quarter On Tuesday, October 30, 2012
3. Griffin Securities Analyst Interviews Unilife Corp. CEO in a Two-Part Video Series
4. Unilife Corporation Announces Financial Results For Fiscal Year 2012 Fourth Quarter
5. Unilife Corporation to Announce Financial Results for Fiscal 2012 Fourth Quarter and Year End on Monday, July 30, 2012
6. Unilife Granted Key U.S. Patent for Unifill Prefilled Syringe
7. Unilife Signs Long-Term Supply Contract for the Unifill Prefilled Syringe
8. Volcano Corporation Schedules Third Quarter Conference Call, Webcast
9. Harvest Technologies Corporation reicht Patentverletzungsklage gegen ThermoGenesis Corporation ein
10. Harvest Technologies Corporation Files Patent Infringement Complaint against ThermoGenesis Corporation
11. Sosei Group Corporation: QVA149 Filed as a Once-Daily Maintenance Treatment for COPD in Europe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... Feb. 4, 2016  SciClone Pharmaceuticals, Inc. (NASDAQ: ... has entered into a settlement agreement with the ... resolving the SEC,s investigation into possible violations of ... terms of the settlement agreement, SciClone has agreed ... disgorgement, pre-judgment interest and a penalty.  This payment ...
(Date:2/4/2016)... -- Global Immunology Market to 2022 - Large ... growth Summary Immune-mediated inflammatory diseases are ... affect 5–7% of western populations. Although they are ... key patient demographics, they are pathophysiologically linked, being ... inappropriate immune response. Generally, disease-modifying anti-rheumatic drugs, a ...
(Date:2/4/2016)...  Aethlon Medical, Inc. (Nasdaq: AEMD ), ... treat life-threatening diseases, today announced results for the ... 2015. --> --> ... our last quarterly call, we strategically advanced pre-clinical ... to establish the Aethlon Hemopurifier® as a leading ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... Boar’s Head Brand®, one of the ... this weekend’s Big Game. Take the stress out of your party preparation – follow ... happy at every stage of the game. , “The key to hosting a successful ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... CitiDent, announces that it is now welcoming orthodontist, Dr. Amanda Cheng, to ... a complete range of oral health care, including general dentistry, cosmetic treatments, periodontics, ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... ... Care for Patients with Rare Diseases, a continuing medical education (CME) event presented ... the first of its kind—and a first for ACCORD, whose mission is to ...
(Date:2/5/2016)... ... 05, 2016 , ... When one is tired of trying to cram belongings into spare space ... to rent a storage unit, but before hastily spending money on a unit, take these ... more space. But what one is often not told when utilizing these services are some ...
(Date:2/4/2016)... ... February 04, 2016 , ... True Health Initiative (THI), ... the creation of the THI Media Response Team (MRT). The primary mission of the ... and influencers about the fundamentals of healthy, sustainable eating, and other aspects of lifestyle ...
Breaking Medicine News(10 mins):